HOME >> MEDICINE >> NEWS
Initial results help clinicians identify patients with treatment-resistant depression

Initial results of the nation's largest clinical trial for depression have helped clinicians to track "real world" patients who became symptom-free and to identify those who were resistant to the initial treatment. Participants treated in both medical and specialty mental health care settings experienced a remission of symptoms in 12 to 14 weeks during well-monitored treatment with an antidepressant medication. The study, funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH), used flexible adjustment of dosages based on quick and easy-to-use clinician ratings of symptoms and patient self-ratings of side effects.

About a third of participants reached a remission or virtual absence of symptoms during the initial phase of the study, with an additional 10 to 15 percent experiencing some improvement. Subsequent phases of the trials will help determine successful treatments for the nearly two thirds of those patients who were identified as treatment-resistant to a first medication in phase one.

The trial, known as the STAR*D study -- Sequenced Treatment Alternatives to Relieve Depression -- included 2,876 participants and was conducted over six years at a cost of $35 million. (For more information on STAR*D, go to: http://www.clinicaltrials.gov/ct/show/NCT00021528?order=1).

The medication used in this first phase of the study was the serotonin reuptake inhibitor (SSRI) citalopram (Celexa, made by Forest Pharmaceuticals), and response rates were comparable across the 23 psychiatric and 18 primary care treatment sites. John Rush, M.D., and Madhukar Trivedi, M.D., of the University of Texas Southwestern Medical Center (UTSMC), and colleagues report on the results of phase 1 of STAR*D in the January, 2005 American Journal of Psychiatry.

"The real goal of STAR*D is how best to help the 70 percent of patients for whom treatmen
'"/>

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
1-Jan-2006


Page: 1 2 3 4

Related medicine news :

1. UCLA Stroke Center receives American Stroke Associations Initial Achievement Award
2. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
3. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
4. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
5. Targeted, oral agent Enzastaurin shows favorable results
6. Childhood obesity intervention shows promising results
7. Alpharma presents positive pharmacokinetic study results
8. UCSF brain tumor vaccine trial shows promising results
9. The eyes have it -- Autism research yields surprising results
10. ACP: Residency match results for internal medicine underscore need to redesign primary care
11. Positive results more likely from industry-funded breast cancer trials

Post Your Comments:
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The more hours young adults spend ... mass index and bigger waist circumference, a 15-year analysis by the University of Pittsburgh ... in later years, indicating that young adulthood is an important time to intervene and ...
(Date:8/31/2015)... York (PRWEB) , ... August 31, 2015 , ... With ... when play-offs and the World Series will dominate the sports world. Fans desire nothing ... eventually advance to the final series. For children, especially those who are too young ...
(Date:8/31/2015)... ... 31, 2015 , ... Castle Dermatology Institute now welcomes San Fernando Valley ... graduate of the University of California, Los Angeles. He graduated summa cum laude with ... California, Irvine Medical School. As a nationally recognized Regents Scholar, Dr. Ghasri was given ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... 2015 in September by sharing the facts about the role of heredity in ... BRCA2 genetic mutations because of Angelina Jolie Pitt’s decisions to have both her ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
Cached News: